Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update
Bicycle Therapeutics (NASDAQ: BCYC) announced upcoming presentations of data for zelenectide pevedotin at the 2024 San Antonio Breast Cancer Symposium. The company will present findings showing enhanced anti-tumor activity in triple-negative breast cancer patients with NECTIN4 gene amplification.
Additionally, Bicycle will announce topline data for zelenectide pevedotin plus pembrolizumab combination in first-line metastatic urothelial cancer patients, and monotherapy results in non-small cell lung cancer patients. The poster presentation, led by Dr. Niklas Klümper from University Hospital Bonn, is scheduled for December 12. A conference call to discuss these updates will be held on December 13.
Bicycle Therapeutics (NASDAQ: BCYC) ha annunciato le prossime presentazioni dei dati per zelenectide pevedotin al Simposio sul Cancro al Seno di San Antonio 2024. L'azienda presenterà risultati che mostrano un'attività anti-tumorale potenziata nei pazienti affetti da cancro al seno triplo negativo con amplificazione del gene NECTIN4.
In aggiunta, Bicycle annuncerà i dati preliminari per la combinazione di zelenectide pevedotin e pembrolizumab nei pazienti con cancro uroteliale metastatico in prima linea, e i risultati della monoterapia nei pazienti con cancro polmonare non a piccole cellule. La presentazione del poster, condotta dal dott. Niklas Klümper dell'Ospedale Universitario di Bonn, è programmata per il 12 dicembre. Una conferenza telefonica per discutere questi aggiornamenti si terrà il 13 dicembre.
Bicycle Therapeutics (NASDAQ: BCYC) anunció las próximas presentaciones de datos sobre zelenectide pevedotin en el Simposio sobre Cáncer de Mama de San Antonio 2024. La compañía presentará hallazgos que muestran una actividad antitumoral mejorada en pacientes con cáncer de mama triple negativo con ampliación del gen NECTIN4.
Además, Bicycle anunciará los datos preliminares de la combinación de zelenectide pevedotin más pembrolizumab en pacientes con cáncer urotelial metastásico de primera línea, así como los resultados de la monoterapia en pacientes con cáncer de pulmón no microcítico. La presentación del cartel, liderada por el Dr. Niklas Klümper del Hospital Universitario de Bonn, está programada para el 12 de diciembre. Una llamada conferencia para discutir estas actualizaciones se llevará a cabo el 13 de diciembre.
자전거 치료제(Bicycle Therapeutics) (NASDAQ: BCYC)는 2024년 샌안토니오 유방암 심포지엄에서 젤레넥타이드 페베도틴(zelenectide pevedotin)에 대한 데이터 발표를 예정하고 있다고 발표했습니다. 이 회사는 NECTIN4 유전자 증폭이 있는 삼중 음성 유방암 환자에서 향상된 항종양 활성을 보여주는 결과를 발표할 예정입니다.
또한, 바이시클은 1차 전이성 요로 상피암 환자에서 젤레넥타이드 페베도틴과 펨브롤리주맙(pembrolizumab) 조합의 주요 데이터와 비소세포 폐암 환자에서의 단독 요법 결과를 발표할 것입니다. 포스터 발표는 본 대학교 병원의 닉라스 클럼퍼 박사가 주도하며, 12월 12일에 예정되어 있습니다. 이러한 업데이트를 논의하기 위한 컨퍼런스 콜은 12월 13일에 진행될 것입니다.
Bicycle Therapeutics (NASDAQ: BCYC) a annoncé les prochaines présentations de données concernant zelenectide pevedotin lors du Symposium sur le cancer du sein de San Antonio 2024. L'entreprise présentera des résultats montrant une activité anti-tumorale améliorée chez les patientes atteintes de cancer du sein triple négatif avec amplification du gène NECTIN4.
De plus, Bicycle annoncera des données préliminaires sur la combinaison de zelenectide pevedotin et pembrolizumab chez des patientes atteintes de cancer urotéhal métastatique en première ligne, ainsi que les résultats en monothérapie chez des patientes atteintes de cancer du poumon non à petites cellules. La présentation des affiches, dirigée par le Dr Niklas Klümper de l'Hôpital Universitaire de Bonn, est prévue pour le 12 décembre. Une conférence téléphonique pour discuter de ces mises à jour se tiendra le 13 décembre.
Bicycle Therapeutics (NASDAQ: BCYC) gab die bevorstehenden Präsentationen von Daten zu zelenectide pevedotin beim 2024 San Antonio Breast Cancer Symposium bekannt. Das Unternehmen wird Ergebnisse präsentieren, die eine verbesserte antitumorale Aktivität bei Patienten mit dreifach negativem Brustkrebs und NECTIN4-Genamplifikation zeigen.
Zusätzlich wird Bicycle die vorläufigen Ergebnisse der Kombination von zelenectide pevedotin und Pembrolizumab bei Patienten mit metastasierendem Urothelkarzinom in der Erstlinientherapie sowie die Monotherapie-Ergebnisse bei Patienten mit nicht-kleinzelligem Lungenkrebs bekannt geben. Die Posterpräsentation, geleitet von Dr. Niklas Klümper vom Universitätsklinikum Bonn, ist für den 12. Dezember geplant. Eine Telefonkonferenz zur Diskussion dieser Aktualisierungen findet am 13. Dezember statt.
- None.
- None.
Abstract outlines data showing enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer patients with NECTIN4 gene amplification
Company to announce topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer and topline monotherapy data for zelenectide pevedotin in non-small cell lung cancer
Conference call and webcast scheduled for Friday, Dec. 13, at 7 a.m. CT to review all data
In conjunction with the SABCS poster presentation, Bicycle Therapeutics will also announce topline combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer, and topline monotherapy data for zelenectide pevedotin in non-small cell lung cancer patients with NECTIN4 gene amplification. The company will host a conference call and webcast for analysts and investors to review the updated data for zelenectide pevedotin.
Poster Presentation:
Title: Enhanced anti-tumor activity of zelenectide pevedotin in triple negative breast cancer (TNBC) patients (pts) with NECTIN4 gene amplification (amp)
Session Number: 4
Date and Time: Thursday, Dec. 12, at 5:30-7 p.m. CT
Presentation Number: P4-10-21
Lead Author: Niklas Klümper, M.D., University Hospital Bonn
Conference Call and Webcast Information
Bicycle Therapeutics will host a conference call and webcast on Friday, Dec. 13, at 7 a.m. CT to review the data updates for zelenectide pevedotin. To access the call, please dial +1-833-816-1408 (
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241125297563/en/
Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
stephanie.yao@bicycletx.com
857-523-8544
Matthew DeYoung
Argot Partners
ir@bicycletx.com
212-600-1902
Media:
Jim O’Connell
Weber Shandwick
media@bicycletx.com
312-988-2343
Source: Bicycle Therapeutics plc
FAQ
What data will Bicycle Therapeutics (BCYC) present at the 2024 San Antonio Breast Cancer Symposium?
When is Bicycle Therapeutics (BCYC) scheduled to present at the 2024 SABCS?
What additional data will Bicycle Therapeutics (BCYC) announce alongside the SABCS presentation?
When is Bicycle Therapeutics (BCYC) hosting their conference call to discuss the zelenectide pevedotin data?
